<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01180764</url>
  </required_header>
  <id_info>
    <org_study_id>00040562</org_study_id>
    <nct_id>NCT01180764</nct_id>
  </id_info>
  <brief_title>Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia</brief_title>
  <official_title>Effects of Lovaza Monotherapy vs. Placebo on Composition and Function of HDL and Other Lipoproteins, and on Other Lipid-Related Parameters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study hypothesis: Lovaza (purified prescription fish oil) is likely to help HDL (the &quot;good
      cholesterol&quot;) work better.

      Study summary: We are testing effects of Lovaza versus placebo, on various aspects of HDL and
      other lipoproteins, in patients with high triglyceride levels.

      Study funding: This study is being funded by an investigator-initiated research grant from
      Glaxo Smith Kline.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Withdrawn for administrative reasons.
  </why_stopped>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HDL Composition</measure>
    <time_frame>12 weeks</time_frame>
    <description>HDL composition (protein and lipid) by size (gel filtration column)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HDL cholesterol composition by density subfraction</measure>
    <time_frame>12 weeks</time_frame>
    <description>HDL composition by density gradient ultracentrifugation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>12 weeks</time_frame>
    <description>Transaminases and glucose levels</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hypertriglyceridemia</condition>
  <arm_group>
    <arm_group_label>Lovaza</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lovaza 4g po qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovaza (Omega-3 acid ethyl esters)</intervention_name>
    <description>1g capsules, 4 capsules po daily</description>
    <arm_group_label>Lovaza</arm_group_label>
    <other_name>Lovaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching active lovaza, 1 g capsules, 4 capsules po daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Fasting TG 500-2000 mg/dL (off of TG-lowering medicationsâ€”see below)

          -  Age 35-75 years

        Exclusion criteria:

          -  Use of Lovaza (2g/d or more) or high-dose dietary supplement omega-3 oil (4g/d or
             more) in the past 2 months

          -  Use of lipid therapy (statin, ezetimibe, fibrate, BAS, or niacin at therapeutic dose,
             1g/d or higher) in the past 3 weeks (washout of prior therapy permitted)

          -  Anticipated need to change type or dose of BP medicine (all types allowed), of
             lipid-active diabetes medication (thiazolidinedione), of oral estrogen (BCP or HRT),
             or glucocorticoid during the study (16 + 2 weeks = 18 weeks total)

          -  Excess ethanol consumption (regular intake &gt;4 drinks/d, or binges of &gt;8 drinks at once
             for men, half these levels for women)

          -  Poorly controlled diabetes mellitus (A1c &gt;9%)

          -  History of acute or chronic pancreatitis

          -  Use of exenatide (Byetta) or sitagliptin (Januvia), medications believed to increase
             the risk of acute pancreatitis

          -  History of significant unexplained or uncontrolled bleeding or bruising

          -  Poorly controlled blood pressure (&gt;140/90mmHg, with or without treatment)

          -  Poorly controlled thyroid disease (TSH outside of normal range)

          -  Hepatic disease (ALT &gt; 2.5x ULN, Dx of hepatitis or cirrhosis)

          -  Any contraindication or prior adverse reaction to Lovaza

          -  Active cancer (except basal cell or squamous cell skin cancer)

          -  Pregnancy, plan/desire to become pregnant, breast feeding

          -  Inability or unwillingness to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eliot A Brinton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2010</study_first_submitted>
  <study_first_submitted_qc>August 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2010</study_first_posted>
  <last_update_submitted>February 4, 2016</last_update_submitted>
  <last_update_submitted_qc>February 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2016</last_update_posted>
  <responsible_party>
    <name_title>Eliot A. Brinton, MD</name_title>
    <organization>University of Utah</organization>
  </responsible_party>
  <keyword>hypertriglyceridemia</keyword>
  <keyword>omega-3 acid ethyl esters</keyword>
  <keyword>high-density lipoproteins</keyword>
  <keyword>fish oil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertriglyceridemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

